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 Report summary 20 
 Presentation for investigation and/or treatment of respiratory disease comprised 0.9 per cent, 21 
1.2 per cent and 1.2 per cent of total dog, cat and rabbit consultations respectively between 1 22 
January 2018 and 28 February 2019. 23 
 Coughing was the most frequently recorded respiratory disease clinical sign in dogs (68.0 per 24 
cent of cases), whereas sneezing was most common in cats (45.6 per cent of cases). 25 
 The proportion of respiratory disease consultations which prescribed antibiotics authorised for 26 
systemic administration (including oral and injectable formulations) decreased between April 27 
2014 and February 2019 by approximately 25 per cent. 28 
 Between January 2016 and February 2019, 14.5 per cent of 1,602 canine and 4.9 per cent 29 
of 801 feline respiratory samples submitted to UK-based diagnostic laboratories tested 30 
positive for presence of Bordetella bronchiseptica. 31 
 32 
About this report 33 
This report is the eighth in a series by the Small Animal Veterinary Surveillance Network 34 
(SAVSNET). The other reports in the series are available from http://veterinaryrecord.bmj.com. 35 
As data are collected for longer periods, the estimates of changes in disease burden will become 36 
more refined, allowing more targeted local and perhaps national interventions. Anonymised data 37 
can be accessed for research by contacting the authors. SAVSNET also welcomes feedback on 38 
this report. More information about SAVSNET is available at www.liverpool.ac.uk/savsnet39 
 Syndromic surveillance of respiratory disease 40 
This report represents the third occasion the Small Animal Veterinary Surveillance Network 41 
(SAVSNET) has summarised respiratory disease in companion animals (Arsevska and others 42 
2018a; Sánchez-Vizcaíno and others 2016). The present report considers electronic health 43 
records (EHRs) captured by the SAVSNET project from 227 voluntary veterinary practices 44 
(484 sites) over a 14-month period from 1 January 2018 to 28 February 2019. A detailed 45 
description of the methodology used by SAVSNET to capture EHRs has been previously 46 
provided (Sánchez-Vizcaíno and others 2015 and 2017). A total of 1,710,078 consultations 47 
were analysed, of which 70.2 per cent were from dogs, 26.6 per cent were from cats, 1.7 per 48 
cent were from rabbits, and the remaining 1.5 per cent were from other species, or where species 49 
was not recorded. Animals mainly presenting for investigation and/or treatment of respiratory 50 
disease according to the attending veterinary surgeon or nurse comprised 0.9 per cent, 1.2 per 51 
cent and 1.2 per cent of total dog, cat and rabbit consultations respectively. 52 
 53 
Short questionnaires (Sánchez-Vizcaíno and others 2016) were completed by the attending 54 
practitioner after 3,937 random respiratory disease consultations (2,404 canine, 1,177 feline, 55 
3,707 unique animals). Of these dogs, 52.2 per cent were being presented for the first time after 56 
a history of illness of up to one week (47.2 per cent). Though cats also tended to present most 57 
commonly following illness of up to one week (41.6 per cent), most were for revisits / check-58 
ups (52.3 per cent). For both dogs and cats, the second most common duration of respiratory 59 
clinical signs was one month or longer (20.5 per cent of dogs, 32.3 per cent of cats). Whilst by 60 
far the most common presenting clinical sign in dogs was coughing, sneezing was most 61 
commonly observed in cats (Table 1). A minority of dogs (6.3 per cent) and cats (3.6 per cent) 62 
were reported as having stayed in a kennel or cattery within the preceding 10 days. 63 
 64 
Consulting veterinary surgeons considered cases likely to be respiratory in origin in over 71.2 65 
per cent of canine and 78.4 per cent of feline cases, with a cardiac origin being considered likely 66 
in 15.3 and 7.8 per cent of canine and feline cases respectively. Diagnostic testing was planned 67 
in 23.5 per cent of canine and 22.9 feline cases, with radiography being the most common in 68 
both dogs (6.8 per cent) and cats (7.2 per cent). Biochemistry and / or haematology were also 69 
relatively commonly planned. These findings were broadly consistent with SAVSNET’s 70 
previous reports (Arsevska and others 2018a; Sánchez-Vizcaíno and others 2016). 71 
 72 
Spatial distribution of respiratory disease 73 
 The spatial distribution of the relative risk for respiratory disease was evaluated in dogs and 74 
cats in England, Scotland and Wales for each season of the surveillance period between 1 75 
January 2018 and 28 February 2019. For consultations with a valid owner postcode the centroid 76 
of each postcode was used to indicate the approximate residence of each recorded animal. 77 
Hence, these centroids were aggregated into 20km gridded cells encompassing England, 78 
Scotland and Wales, calculating the proportion of total consultations mainly presenting with 79 
respiratory disease. Standard error (SE) for each cell was calculated to provide a measure of 80 
relative confidence in findings due to variable geographic consultation coverage, with these 81 
values being used to formulate septile bi-variate maps, where the darkest red colours indicate 82 
highest proportions of respiratory disease (greater than 1.8 per cent and 2.7 per cent for dogs 83 
and cats respectively) and lowest standard errors (Fig.1). As previously observed (Arsevska and 84 
others 2018a; Sánchez-Vizcaíno and others 2016), transient regions of increased respiratory 85 
disease incidence were distributed seemingly randomly throughout the country and in most 86 
seasons. In future, SAVSNET will need to work with others to develop robust statistical and 87 
practical methods to determine whether these transient increases in respiratory disease 88 
prevalence represent actual infectious disease outbreaks. 89 
 90 
Respiratory disease pharmacosurveillance 91 
For the first time in this report we also analysed pharmaceutical product prescriptions given 92 
during all respiratory consultations recorded between April 1 2014 and February 28 2019 in 93 
dogs (n = 46,200 respiratory consultations), cats (n = 23,113) and rabbits (n = 1,448). A semi-94 
automated text mining methodology was utilised to identify the active substance(s) dispensed 95 
in each consultation using the ‘product dispensed’ field of the EHR; these active substances 96 
were summarised into a hierarchical pharmaceutical classification system as previously 97 
described (Singleton and others 2018; Singleton and others 2017). For the purposes of this 98 
report, five pharmaceutical families of particular relevance to respiratory disease were analysed, 99 
including antibiotics authorised for systemic (oral or injectable) use; anti-inflammatories 100 
authorised for systemic use; respiratory-active (R-A) products (e.g. bronchodilators); 101 
cardiovascular-active (CV-A) products (e.g. diuretics), and euthanasia. 102 
 103 
For dogs, systemic antibiotics were prescribed in 37.4 per cent of respiratory consultations, 104 
systemic anti-inflammatories in 34.6 per cent, R-A products in 5.0 per cent, and CV-A products 105 
in 12.7 per cent. For cats, systemic antibiotics were prescribed in 48.5 per cent of respiratory 106 
consultations, systemic anti-inflammatories in 21.7 per cent, R-A products in 8.4 per cent, and 107 
 CV-A products in 7.3 per cent. For rabbits, systemic antibiotics were prescribed in 64.7 per 108 
cent of respiratory consultations, systemic anti-inflammatories in 21.7 per cent, R-A products 109 
in 4.0 per cent, and CV-A products in 0.7 per cent. Dogs were euthanised in 1.2 per cent of 110 
respiratory consultations, compared to 2.4 per cent of cat and 4.2 per cent of rabbit respiratory 111 
consultations. 112 
 113 
Temporal trends in prescription frequency were also examined in dogs and cats (Fig.2). Over 114 
the five years analysed, an approximately 25 per cent decrease in the frequency with which 115 
systemic antibiotics were prescribed was noted in this population, with other pharmaceutical 116 
families remaining broadly static over the same time period. Systemic antibiotic and anti-117 
inflammatory prescription frequency tended to peak in the 3rd or 4th quarter of each year for 118 
dogs suggesting a seasonality to the occurrence of perceived antibiotic responsive disease; such 119 
a trend was less discernible for cats. 120 
 121 
Laboratory-based investigations of Bordetella bronchiseptica in companion animals 122 
SAVSNET collated data from four participating UK-based veterinary diagnostic laboratories 123 
(VDL) between 1 January 2016 and 28 February 2019, with data being used to identify temporal 124 
and spatial trends in the proportion of respiratory sample submissions that tested positive (as 125 
interpreted by the VDL) for presence of Bordetella bronchiseptica (B. bronchiseptica) by 126 
quantitative polymerase chain reaction (qPCR) assay. In total there were 1,602 recorded canine 127 
and 801 recorded feline tests completed, 14.5 per cent (n=233) and 4.9 per cent (n=39) testing 128 
positive respectively. 129 
 130 
Over the three years, the proportion of positive results was relatively static (Fig.3). For both 131 
dogs and cats, a greater proportion of tests completed in winter were positive (dogs: 17.3 per 132 
cent; cats: 7.6 per cent), followed by summer (dogs: 14.1 per cent; cats: 4.7 per cent), autumn 133 
(dogs: 13.6 per cent; cats: 3.8 per cent) and spring (dogs: 12.9 per cent; cats: 2.8 per cent). Due 134 
to a low number of feline positive results, spatial trends were examined for dogs alone. 135 
Collating all tests from 2016 to 2019, though varied coverage should be considered, both areas 136 
of relatively high and low positive test proportions were revealed in postcode areas for which 137 
we hold relatively high volumes of data (low standard error); this suggests variable B. 138 
bronchiseptica infection risk in different regions of the country (Fig.4). To our knowledge it 139 
has been many years since B. bronchiseptica infection has been surveyed in companion animals 140 
in the UK, though a 2005 European-wide survey of cats in catteries found a comparative (5 per 141 
 cent) B. bronchiseptica prevalence in cats suffering from upper respiratory tract disease (Helps 142 
and others 2005). 143 
 144 
Update on main presenting complaint temporal trends in companion animals 145 
An observed prevalence time series for three key main presenting complaints (pruritus, 146 
gastroenteric and respiratory) from February 2017 to February 2019 is shown in Figure 5, 147 
together with a seasonal trend line (dark grey line). The trend line was calculated using a 148 
Bayesian binomial generalised linear model trained on weekly prevalence between 2014 and 149 
2019, as fully described previously (Arsevska and others 2018b). Extreme prevalence 150 
observations describing weekly prevalence exceeding 99 per cent credible intervals, and 151 
moderate prevalence observations describing weekly prevalence exceeding 95 per cent credible 152 
intervals are displayed in red and orange respectively.  153 
 154 
These results show continued seasonal prevalence fluctuations in both species, particularly 155 
apparent for pruritus in both dogs and cats, and respiratory disease in dogs. In dogs and cats, 156 
this seasonal pattern for pruritus appeared generally stable, though both species reported a few 157 
extreme case increase weeks in January 2019. Respiratory disease was less stable, suggesting 158 
an extreme increase above expected levels in respiratory cases in dogs and cats at the beginning 159 
of 2019. It is currently unknown whether these findings represent a true increase in disease 160 
prevalence, or reflect the changing nature of participation in the SAVSNET project. 161 
 162 
Global perspective 163 
Aujeszky’s disease in a dog 164 
An 18-month-old Munsterlander was killed by Aujeszky's disease virus after a hunt in Moselle 165 
in February. The disease, caused by an alphaherpesvirus, can be transmitted from wild boars to 166 
domestic carnivores. The UK was declared disease free in 2012, but the virus persists in some 167 
wild populations of pigs in parts of mainland Europe. In dogs and cats, clinical signs include 168 
frantic and traumatic scratching, followed by paralysis and death; their similarity to those of 169 
rabies leading to the disease’s other name – pseudorabies. In dogs, disease is rare and most 170 
likely in hunting dogs. However, Aujeszky’s disease is notifiable, and although unlikely, this 171 
case serves to remind us of the potential of this disease in dogs (and cats) returning from places 172 
where the disease is endemic. Promed Archive Number: 20190218.6323356 173 
 174 
Carbapenemase-producing Enterobacteriaceae in dogs 175 
 Carbapenems are considered a highest priority critical antibiotic used to treat already multidrug 176 
resistant infections in people. However, their use has led to the emergence of carbapenemase-177 
producing Enterobacteriaceae (CPE) which represent a serious public health problem. 178 
Carbapenems are not authorised for veterinary patients in the UK. As a result, there is limited 179 
carbapenem susceptiblity testing conducted on companion animal-derived clinical isolates in 180 
veterinary diagnostic labs, nor any formal national surveillance of carbapenemase production 181 
in companion animals in the UK. Researchers have now isolated a carbapenemase-producing 182 
E. coli from a UK practice-derived veterinary culture collection (Reynolds and others 2019). 183 
From one isolate, originally from a skin wound in a Springer Spaniel, researchers identified a 184 
known carbapenem resistance gene (blaNDM-5). The gene was located on the same plasmid as 185 
other genes conferring resistance to other antimicrobial classes, potentially demonstrating co-186 
selection and maintenance of carbapenem resistance with use of other antimicrobials in 187 
companion animals. This finding highlights the perhaps growing potential of antibiotic use in 188 
pet animals to impact on human health. 189 
 190 
Update on Canine Infectious Respiratory Disease complex and Bordetella bronchiseptica 191 
infection in dogs 192 
Background 193 
B. bronchiseptica is a gram negative, aerobic coccobacillus. It forms part of the “kennel cough” 194 
or Canine Infectious Respiratory Disease complex (CIRDc), the names given to commonly seen 195 
signs of upper respiratory tract infections in dogs. Despite its name, the syndrome is not 196 
confined to kennels and may be transmitted anywhere where dogs mix, including shows, 197 
training classes, parks and veterinary surgeries. Pathogenesis of CIRDc is thought to frequently 198 
involve initial infection with an upper respiratory tract pathogen such as canine respiratory 199 
coronavirus (CRCoV) or canine parainfluenza virus (CPiV). This then facilitates secondary 200 
infection, often with opportunistic organisms already present in the respiratory tract, such as 201 
Mycoplasma cynos. B. bronchiseptica may play the role of either primary pathogen or 202 
secondary invader. In some parts of world, canine influenza viruses also contribute; these are 203 
not yet thought to be regularly circulating in the UK ( Sánchez-Vizcaíno and others 2016). 204 
 205 
Clinical signs 206 
A hacking cough is clinically typical of CIRDc, though not pathognomonic of any one 207 
pathogen. Differentials include retching, regurgitation and oropharyngeal foreign body. In 208 
addition to the cough, dogs may have submandibular lymph node enlargement and mild 209 
 pyrexia. Whilst affected animals typically remain bright and well, in severe cases or particularly 210 
susceptible individuals, bronchopneumonia can occur, with associated increased respiratory 211 
effort, pyrexia and lethargy. Deaths are relatively uncommon. Where outbreaks of severe 212 
disease occur, aspects of husbandry such as ventilation, stress and biosecurity should be 213 
assessed and alternative pathogens such as Streptococcus equi zooepidemicus considered. 214 
 215 
Diagnosis 216 
Diagnosis of CIRDc is usually made by the presence of characteristic clinical signs. Diagnostic 217 
testing is indicated in the presence of an outbreak, where the results could inform a change in 218 
policy (such as therapy or vaccination), or in individual cases where signs are severe or fail to 219 
resolve. For upper respiratory tract disease, a deep oropharyngeal swab should be taken. A 220 
number of PCR panel tests are available, and can be helpful in checking for the presence of 221 
several organisms simultaneously. Diagnostic results need to be interpreted with care since 222 
some of the components of CIRDc can be part of normal respiratory tract flora. Additionally, 223 
CIRDc may involve different pathogens at different stages of infection. Therefore, in an 224 
outbreak, sampling several dogs at different stages of infection may be helpful.  225 
 226 
Treatment 227 
For most dogs with CIRDc, specific antibiotic therapy is not necessary, with symptomatic 228 
treatment (avoiding pulling on collars, rest and NSAIDS if needed) being sufficient. Use of 229 
antitussives is contentious. International Society for Companion Animal Infectious Diseases 230 
(ISCAID) guidelines suggest empirical use of antibiotics where there is a mucopurulent 231 
discharge alongside signs of lethargy, pyrexia or anorexia (Lappin and others 2017). BSAVA 232 
PROTECT ME suggests that antibiotics are only indicated if clinical signs persist for greater 233 
than 10 days and/or the dog is systemically unwell (BSAVA/SAMSoc 2018).  Where necessary, 234 
both guidelines suggest doxycycline or potentiated amoxycillin as the first choice antibiotics. 235 
Where cases fail to resolve, or if the lower respiratory tract is involved, culture and sensitivity 236 
and further investigations such as broncho-alveolar lavage may be indicated. 237 
 238 
Control 239 
Several pathogens involved in CIRDc are part of canine core vaccines. In the UK, Bordetella 240 
vaccination is given intranasally, often combined with CPiV; elsewhere subcutaneous and oral 241 
vaccines exist. Mucosal immunity commences within three days. As the vaccine is live, some 242 
dogs may have a transient cough for several days afterwards. It is essential to note that 243 
 vaccination will not fully prevent clinical CIRDc due to the range of pathogens which contribute 244 
to this syndrome. Following natural infection, dogs may shed Bordetella at diminishing levels 245 
for up to 12 weeks, with transmission mainly via aerosol. Therefore restricting social mixing of 246 
dogs recovering from CIRDc is important in limiting spread. 247 
 248 
Zoonotic potential and cross-species transmission 249 
B. bronchiseptica is a rare but potentially serious zoonosis (Garcia-de-la-Fuente and others 250 
2015). Case reports of infections in cystic fibrosis and transplant patients have documented 251 
serious sequelae and even death (Brady and others 2014; Ner and others 2003). Zoonotic 252 
transmission following vaccination (including the administrator, handler and owner) is thought 253 
to be possible but extremely rare (Gisel and others 2010). Post-vaccination shedding may occur 254 
for several weeks (Iemura and others 2009). Where immunocompromised humans are in 255 
contact with dogs, the low but predictable risk of vaccination must be carefully weighed against 256 
the less predictable risk of clinical infection. Appropriate advice, including recommending at-257 
risk owners contact their medical practitioner, should be offered. 258 
 259 
Transmission between dogs and cats has been suggested to occur (Binns and others 1999). 260 
Additionally, cats have also been implicated in zoonotic infections (Register and others 2012). 261 
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 Tables 274 
Table 1: Percentage of recorded clinical signs in 2,404 dog and 1,177 cat consultations 275 
presented with respiratory disease to veterinary practices in the UK (January 1, 2018 to 276 
February 28, 2019).* 277 
Clinical sign Number (%) of dogs Number (%) of cats 
Coughing 1631 (68.0) 333 (28.3) 
Dyspnoea 328 (13.7) 246 (20.9) 
Sneezing 303 (12.6) 536 (45.6) 
Nasal discharge 212 (8.8) 347 (29.4) 
Conjunctivitis and/or ocular discharge 42 (1.7) 170 (14.5) 
Drooling 61 (2.5) 40 (3.4) 
Mouth ulcers 4 (0.2) 11 (0.9) 
Pyrexia 79 (3.3) 54 (4.6) 
Generalised depression / lethargy 143 (5.9) 94 (8.0) 
Other clinical signs 330 (13.7) 159 (13.5) 
* The same animal could present with more than one sign per consultation 278 
 Figures 279 
Figure 1: Septile bi-variate maps indicating proportion of total canine and feline consultations 280 
(1 Jan 2018 – 28 Feb 2019) presenting mainly for investigation and/or treatment of respiratory 281 
disease, summarised by 20km gridded cells encompassing England, Scotland and Wales. 282 
Proportion has been modelled against standard error to provide a measure of relative 283 
confidence in findings according to the volume of data collected in each cell. Darker red 284 
colours indicate areas of relatively high confidence and prevalence.  285 
 286 
Figure 2: Percentage of canine and feline respiratory consultations where systemic 287 
antibiotics; systemic anti-inflammatories; respiratory- or cardiovascular-active products were 288 
prescribed, by quarter (Q2 2014 – Q1 2019). Also described are the percentage of respiratory 289 
consultations where the animal was euthanased. Shaded regions refer to 95% confidence 290 
intervals, calculated to adjust for clustering within veterinary practice site (bootstrapped 291 
estimated, n replicates = 5,000). 292 
 293 
Figure 3:  Percentage of canine and feline respiratory sample submissions that tested positive 294 
by PCR for B.bronchiseptica, summarised by quarter and year (2016-2019). Data was 295 
collated from four veterinary diagnostic laboratories situated in the UK. 296 
 297 
Figure 4: Postcode area quintile bivariate map summary of the proportion of canine 298 
respiratory samples testing positive by PCR assay for presence of B.bronchiseptica, modelled 299 
against standard error to account for variable UK surveillance coverage. Samples tested 300 
between 2016 and 2019 were used, summarising data provided by four UK-based veterinary 301 
diagnostic laboratories. Postcode of the submitting veterinary practice site was used in this 302 
summary. 303 
 304 
Fig 5: Observed prevalence for pruritus, gastroenteritis and respiratory disease in cats and 305 
dogs attending SAVSNET-participating practices from February 2017 to February 2019. Red 306 
points represent the extreme outliers (outside the 99 per cent credible interval [CI]), orange 307 
points represent the moderate outliers (outside the 95 per cent CI but within the 99 per cent 308 
CI), and green points represent the average trend (within the 95 per cent CI).309 
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